Cinclus Pharma Holding

PCAB Pipeline Will Revolutionize Severe GERD Treatment Globally

AnalystConsensusTarget

Not Invested

Consensus Narrative from 3 Analysts

Published

24 Aug 25

Updated

24 Aug 25

AnalystConsensusTarget's Fair Value

SEK 61.25

74.6% undervalued

24 Aug

SEK 15.58

-49.0%

0.5%

-49.0%

0.5%

Author's Valuation

SEK 61.3

74.6% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

SEK 61.3

74.6% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

40.90%

Pharma revenue growth rate

0.58%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

4.92%

Calculation

SEK 55.34m

Earnings '28

58.80x

PE Ratio '28

SEK 3.25b

Market Cap '28

SEK 3.25b

Market Cap '28

46.54m

No. shares '28

SEK 69.92

Share Price '28

SEK 69.92 Share Price '28

Discounted to 2025 @ 4.92% p.a.

SEK 60.54

Fair Value '25